Zydus Hospira Oncology gets EIR for its Ahmedabad facility
Drug firm Zydus Cadila today said Zydus Hospira Oncology, a JV between the company and Hospira Inc, has received Establishment Inspection Report (EIR12-07-2018
Zydus Hospira Oncology gets EIR for its Ahmedabad facility
Drug firm Zydus Cadila today said Zydus Hospira Oncology, a JV between the company and Hospira Inc, has received Establishment Inspection Report (EIRStatement Of Investor Complaints For The Quarter Ended June 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Dhaval N. SoniDesignation :- Company Secretary and Compliance OfficerShareholding for the Period Ended June 30, 2018
Zydus Wellness Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2018. For more details, kindly Click hereAdvertisement Of Notice Of Twenty Fourth Annual General Meeting, E-Voting And Book Closure Information.
Please find attached herewith the copies of the advertisement of Notice of Twenty Fourth Annual General Meeting, E-voting and Book Closure information published in the English and Gujarati editions of Financial Express on July 10, 2018.Zydus Cadila gets USFDA's tentative nod for Deferasirox tablets
Drug firm Zydus Cadila today said it has got tentative nod from the US health regulator to market Deferasirox tablets for oral suspension.Zydus CadIntimation Of Cut-Off Date And Notice Of Annual General Meeting.
This is to inform that the members holding shares as on the cut-off date, i.e. July 26, 2018, will be entitled to exercise their voting rights electronically or at the venue of the Annual General Meeting.Revised Declaration In Respect Of Audit Report With An Unmodified Opinion For The Financial Year Ended On March 31, 2018.
Revised Declaration in respect of Audit Report with an unmodified opinion for the Financial Year ended on March 31, 2018.USFDA issues no observation on Zydus Ahmedabad facility
Zydus Cadila's wholly-owned subsidiary Alidac Pharmaceuticals has not received any observation from the US health regulator after the closure of insZydus gets final nod from USFDA for anti-bacterial drug
Zydus Cadila has received final approval from the USFDA to market Doxycycline Hyclate capsules USP, antibiotic used for treating bacterial infections.Board Meeting-Outcome of Board Meeting
Declaration in respect of Audit Report with an unmodified opinion for the Financial Year ended on March 31, 2018